State TN
Clinical Trials in Tennessee
Recruiting clinical trials with at least one study location in Tennessee. Data updated daily from ClinicalTrials.gov.
Top Conditions in Tennessee
NCT00341744 N/A
Recruiting
Providing Access to the Visual Environment
Condition
Vision Impairment
Enrollment
795 pts
Location
United States
Sponsor
Vanderbilt University
NCT07207811 Phase 3
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine...
Condition
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Enrollment
1,280 pts
Location
United States, Argentina, Australia
Sponsor
Novo Nordisk A/S
NCT06008093 Phase 3
Recruiting
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combinati...
Condition
Carcinoma, Non-Small-Cell Lung
Enrollment
280 pts
Location
United States
Sponsor
AstraZeneca
NCT06841354 Phase 3
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Comb...
Condition
Triple Negative Breast Neoplasms
Enrollment
1,000 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT07083765 Phase 3
Recruiting
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen ...
Condition
Hypertension
Enrollment
142 pts
Location
United States
Sponsor
Ablative Solutions, Inc.
NCT06660394 Phase 3
Recruiting
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults ...
Condition
Dravet Syndrome
Enrollment
160 pts
Location
United States, Australia, Belgium
Sponsor
Longboard Pharmaceuticals
NCT05770531 Phase 2
Recruiting
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Condition
Metastatic HER2-Negative Breast Carcinoma
Enrollment
160 pts
Location
United States
Sponsor
Vanderbilt-Ingram Cancer Cente
NCT06749457 Phase 1, Phase 2
Recruiting
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase...
Condition
Staphylococcus Aureus
Enrollment
231 pts
Location
United States
Sponsor
AstraZeneca
NCT06962800 Phase 3
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in A...
Condition
Primary Membranous Nephropathy
Enrollment
180 pts
Location
United States, Argentina, Australia
Sponsor
Biogen
NCT06203600 Phase 2, Phase 3
Recruiting
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophage...
Condition
Advanced Esophageal Adenocarcinoma
Enrollment
224 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT04429542 Phase 1
Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therap...
Condition
Head and Neck Squamous Cell Carcinoma
Enrollment
292 pts
Location
United States, Australia, Canada
Sponsor
Bicara Therapeutics
NCT04752722 Phase 1, Phase 2
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incom...
Condition
Superficial Bladder Cancer
Enrollment
350 pts
Location
United States, Australia, Canada
Sponsor
enGene, Inc.
NCT05862272 Phase 3
Recruiting
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugoli...
Condition
Uterine Fibroids
Enrollment
1,000 pts
Location
United States
Sponsor
Sumitomo Pharma Switzerland Gm
NCT06936696 N/A
Recruiting
Project PAIR: Parent-implemented Articulation Intervention With Recast
Condition
Hearing Impaired Children
Enrollment
10 pts
Location
United States
Sponsor
Vanderbilt University
NCT07015242 Phase 2
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as Fir...
Condition
Lymphoma
Enrollment
65 pts
Location
United States, France, Germany
Sponsor
Juno Therapeutics, Inc., a Bri
NCT06833073 Phase 2
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Ca...
Condition
Urinary Bladder Neoplasms
Enrollment
308 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT04715139 N/A
Recruiting
Evaluate the Continued Safety and Performance of the Foot and Ankle Products
Condition
Hyperpronated Foot
Enrollment
700 pts
Location
United States, Germany, South Africa
Sponsor
Arthrex, Inc.
NCT06651177 Phase 2
Recruiting
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Op...
Condition
Opioid Use Disorder
Enrollment
310 pts
Location
United States
Sponsor
T. John Winhusen, PhD
NCT04862221 Phase 2
Recruiting
TReatment for ImmUne Mediated PathopHysiology
Condition
Acute Liver Failure
Enrollment
163 pts
Location
United States
Sponsor
National Institute of Diabetes
NCT07060716 N/A
Recruiting
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monit...
Condition
Kidney Transplant Rejection
Enrollment
125 pts
Location
United States, Germany
Sponsor
Insight Molecular Diagnostics
NCT05763953 Phase 2
Recruiting
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
Condition
Paroxysmal Supraventricular Tachycardia
Enrollment
60 pts
Location
United States, Canada, Germany
Sponsor
Milestone Pharmaceuticals Inc.
NCT05948566 Phase 2
Recruiting
Strategy for Improving Stroke Treatment Response
Condition
Ischemic Stroke
Enrollment
300 pts
Location
United States
Sponsor
Translational Sciences, Inc.
NCT05955339 N/A
Recruiting
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness C...
Condition
Diabetes Mellitus
Enrollment
1,200 pts
Location
United States
Sponsor
Dartmouth-Hitchcock Medical Ce
NCT06002477 EARLY_Phase 1
Recruiting
Attentional Mechanisms in SCD
Condition
Subjective Cognitive Decline
Enrollment
80 pts
Location
United States
Sponsor
Vanderbilt University Medical
NCT05238922 Phase 1
Recruiting
Study of INCB123667 in Subjects With Advanced Solid Tumors
Condition
Solid Tumors
Enrollment
604 pts
Location
United States, France, Italy
Sponsor
Incyte Corporation